Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Gastrointest Endosc. 2012 Oct;76(4):733-9. doi: 10.1016/j.gie.2012.04.459. Epub 2012 Jun 23.
EMR is commonly performed before radiofrequency ablation (RFA) for nodular dysplastic Barrett's esophagus (BE).
To determine the efficacy and safety of EMR before RFA for nodular BE with advanced neoplasia (high-grade dysplasia [HGD] or intramucosal carcinoma [IMC]).
Retrospective study.
University of North Carolina Hospitals, from 2006 to 2011.
169 patients with BE with advanced neoplasia: 65 patients treated with EMR and RFA for nodular disease and 104 patients treated with RFA alone for nonnodular disease.
EMR, RFA.
Efficacy (complete eradication of dysplasia, complete eradication of intestinal metaplasia, total treatment sessions, RFA treatment sessions), safety (stricture formation, bleeding, and hospitalization).
EMR followed by RFA achieved complete eradication of dysplasia and complete eradication of intestinal metaplasia in 94.0% and 88.0% of patients, respectively, compared with 82.7% and 77.6% of patients, respectively, in the RFA-only group (P = .06 and P = .13, respectively). The complication rates between the 2 groups were similar (7.7% vs 9.6%, P = .79). Strictures occurred in 4.6% of patients in the EMR-before-RFA group. compared with 7.7% of patients in the RFA-only group (P = .53).
Retrospective study at a tertiary-care referral center.
In patients treated with EMR before RFA for nodular BE with HGD or IMC, no differences in efficacy and safety outcomes were observed compared with RFA alone for nonnodular BE with HGD or IMC. EMR followed by RFA is safe and effective for patients with nodular BE and advanced neoplasia.
射频消融 (RFA) 前通常进行内镜下黏膜切除术 (EMR) 以治疗结节性发育不良 Barrett 食管 (BE)。
确定 EMR 联合 RFA 治疗高级别异型增生(高级别异型增生 [HGD] 或黏膜内癌 [IMC])的结节性 BE 的疗效和安全性。
回顾性研究。
北卡罗来纳大学医院,2006 年至 2011 年。
169 例 BE 伴高级别异型增生:65 例接受 EMR 和 RFA 治疗结节性病变,104 例接受 RFA 治疗非结节性病变。
EMR、RFA。
疗效(异型增生完全消除、肠上皮化生完全消除、总治疗次数、RFA 治疗次数)、安全性(狭窄、出血、住院)。
EMR 联合 RFA 治疗后,94.0%和 88.0%的患者分别实现了异型增生和肠上皮化生的完全消除,而 RFA 单药治疗组的相应比例分别为 82.7%和 77.6%(P =.06 和 P =.13)。两组并发症发生率相似(7.7%比 9.6%,P =.79)。EMR 联合 RFA 组有 4.6%的患者发生狭窄,RFA 单药治疗组有 7.7%的患者发生狭窄(P =.53)。
回顾性研究,在三级转诊中心进行。
在接受 EMR 联合 RFA 治疗 HGD 或 IMC 结节性 BE 的患者中,与 RFA 单药治疗 HGD 或 IMC 非结节性 BE 相比,疗效和安全性无差异。EMR 联合 RFA 治疗高级别异型增生的结节性 BE 是安全有效的。